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Abstract 
 
This study was carried out to investigate the cardiovascular effect of administration of antimalarial 
drugs amodiaquine and artesunate and the efficacy of Garcinia kola extract (kolaviron) in protecting against 
such possible effect.  Thirty (30) adult male albino rats divided into six (6) groups were used in this study.  
Groups D, E and F were treated with 100 mg/Kg b. w of the extract twice daily for the first one week and 200 
mg/Kg b. w. /day for the subsequent three (3) weeks.  Amodiaquine (10mg/Kg. b. w. /day) was administered 
orally for four (4) days into rats in groups A and E while rats in groups B and F were treated with artesunate 
(5mg/Kg b. w. /day) for four (4) days.  Group C rats (normal control) were treated with normal saline.  All the 
rats were sacrificed after four (4) weeks treatment period.  Blood was withdrawn by cardiac puncture while the 
liver, kidney, stomach and heart were removed, cleansed and weigh.  Total cholesterol, LDL- cholesterol, HDL- 
cholesterol and triglycerides were measured in the serum, while total fibrinogen, platelet count, red blood cell 
and white blood cell count were measured in the whole blood.  The artherogenic and coronary risk index were 
also determined.  Results indicate that both amodiaquine and artesunate predispose to cardiovascular disease, 
however the effect was more pronounced with artesunate than amodiaquine.  The result also suggests that both 
drugs could increase the risk of coronary and artherogenic diseases and that Garcinia kola do not prevent the 
cardiotoxicity and coronary risk effect. 
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Introduction 
 
Amodiaquine (Camoquine, Parke – Davis) is a 4-aminoquinoline derivative similar to chloroquine and 
has been widely used both in the prophylaxis and treatment of malaria (Pero and Taylor, 2002; WHO, 1990). 
Following serious toxicity associated with its use as prophylaxis, it was withdrawn by the World Health 
Organization (WHO) from the list of drugs for the treatment of malaria during 1990 – 1996 but later re- instated 
in 1996 (Pero and Taylor, 2002).  Aggranulocytosis and liver damage have repeatedly been reported as adverse 
reactions (ADR’s) to amodiaquine (WHO, 1990). The 19th expert committee on malarial reported that 
amodiaquine could be used for treatment if the risk of infection out weigh the potential for ADR’s but still did 
not recommend amodiaquine as first line treatment (WHO, 1993).  Today, the drug is still in use in the tropics 
for malaria therapy (Koech et al., 1989) 
In recent years, increasing attention has been given to therapies combining antimalarial drugs with 
different mode of actions. Amodiaquine has been tested in clinical trials in combination with artesunate or 
sulfadoxine/pyrimethemine with very encouraging results (WHO, 2001). Artesunate is a water soluble 
hemisuccinate derivative of dihydro – artemisinin. Artemisinin is a sesquiterpene lactone isolated from 
Artemisia annua, an herb that has traditionally been used in china for the treatment of malaria (Greenberg, 
2004). Amodiaquine in combination with artesunate is now one option that is recommended by the WHO for 
use in malarial control programmes. Artesunate and other related artemisinin derivatives have been widely used 
with no reports of any serious adverse reactions. Neurotoxicity has however been observed in animal studies but 
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not in human (http://www.malaria_ipca.com).  Cardiovascular disease (CVD) has been described as the major 
cause of morbidity and mortality in adult human being (John et al., 1999).  Epidemiological studies have shown 
that elevated concentrations of serum total cholesterol and LDL-cholesterol, triglycerides, fibrinogen and 
platelet count are independent risk factors for CVD (John et al., 1999; Mark et al., 1999). 
Garcina kola is a medium sized forest tree found throughout West and Central Africa. The seeds are 
eating as refreshing past time in Nigeria and are known to contain high content of biflavonoid compound.  The 
toxicity is very low, the oral 50% lethal dose being above 5000 mg/Kg b. w. (Nwankwo et al, 2000).  The seeds 
known as “bitter kola” or “false kola” are believed to posses’ aphrodisiac properties and are used for the 
treatment of catarrh and abdominal colicky pain (Adaramoye et al., 2005). Considerable experimental evidence 
has been adduced in support of the antihepatotoxic efficacy of kolaviron in animals against such hepatotoxicants 
as paracetamol (Iwu, 1986), carbon tetrachloride, thioacetamide, galactosamine, phallodine, and ethanol 
(Farombi, 2000; Adaramoye et al, 2005).  In a previous study, we also observed the hepatoprotective effect of 
the extract in amodiaquine induced gastric ulceration (Ajani et. al., Unpublished data).   
There has been increasing report of ischaemic heart disease (Khaw and Barret, 1987).  This increase 
may be attributed to an increase in the prevalence of known cardiovascular risk factor including drugs and local 
herbs.  The aim of the present study is to investigate the risk of developing cardiovascular disease risk factors 
with administration of amodiaquine and artesunate and also examine the efficacy of kolaviron in reversing such 
possible symptoms of cardiotoxicity 
 
 
Materials and methods 
Plant materials  
 
Garcina kola seeds (Guttiferae) (voucher No. OPZH 1034g) were obtained locally in Sagamu market 
and certified by the Plant Science Department, Olabisi Onabanjo University, Ago – Iwoye, Nigeria.  The peeled 
seeds (7.5kg) were then sliced, pulverized with an electric blender and dried at 400C in a Gallenkamp drying 
oven 
 
Preparation of Garcina kola extract 
 
The method of Iwu et al (1990) was used in the extraction of Garcina kola seed. The powdered seeds 
were extracted with light petroleum ether in a Soxhlet for 24hours. The defatted dried mare was repacked and 
extracted with acetone. The extract was concentrated and diluted twice its volume with water and extracted with 
ethyl acetate (6 X 300ml). The concentrated ethyl acetate fraction gave a yellow solid known as kolaviron.  
Appropriate dose dilutions were made by suspending the extract in 0.9% NaCl solution while normal saline was 
administered into the control group. 
 
Treatment and care of Animals 
 
Thirty (30) healthy male albino rats weighing between 150 – 220g were used in the study. They were 
all obtained from the animal house, Physiology Department, University of Ibadan, Nigeria and were 
acclimatized for a week. The rats were randomly distributed into six (6) groups. Amodiaquine {Sigma, St. 
Louis, USA} (10 mg/kg b. w. / day) was administered orally into group A for 4days. Group B was treated with 
artesunate {Sigma, St. Louis, USA} (5 mg/kg b. w. /day) orally for 4days. Rats in group C were treated with 
normal saline while those in group D were treated with Garcina kola extract (200 mg/kg b. w. /once daily) for 
4weeks. Rats in group E and F were treated with Garcina kola extract (100 mg/kg b. w.) twice daily for the first 
one (1) week and 200 mg/kg b. w. once daily for the next 3weeks.  In the second week of treatment with 
Garcina kola, amodiaquine (10 mg/kg b. w.) and artesunate (5 mg/kg b. w) was administered orally into group 
E and F rats (respectively) continuously for 4days.  All administrations were carried out with oral intubator.  
Animal care and protocols were in accordance with the guidelines of the Institutional Animal Ethics Committee 
(Committee on care and use of Laboratory animals, 1985).  Animals were housed in individual cages in a 
temperature and humidity controlled room having a 12hr light and dark cycle.  Feed and clean drinking water 
were supply ad libitum. All animals were sacrificed after 4weeks. Blood was withdrawn by cardiac puncture 
into a heparinized bottle.  The blood was centrifuged at 3000g for 10min and the plasma was carefully extracted 
by pastures pipette.  The plasma was stored at 30 to 400C until analyzed.  The livers, kidney, spleen stomach and 
heart were quickly removed cleaned, dried and weighed. 
 
Determination Of Serum Cholesterol, Lipoproteins And Triglyceride 
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Serum total cholesterol was determined using the method of Liebermann (1958).  HDL- cholesterol 
was determined by the precipitation, enzymatic, colorimetric method of Sigma (1991) Triglyceride was 
determined by colorimetric end point of Sigma (1991).  Serum LDL- Lipoprotein was determined by difference.  
Platelet was counted microscopically while plasma fibrinogen was estimated based on clotting by thrombin 
physicochemical transformation.  Atherogenic index was calculated using the formula of Abott et al, (1988) and 
coronary risk index was obtained by the method of Alladi et al, (1989) 
 
Statistics 
 
All results were analyzed by two – tailed student’s t – test. P values of less then 0.05 were considered 
statistically significant. 
 
 
Results 
 
Following administration of artesunate, the relative weight of the heart, the kidney and the spleen were 
noticed to increase.  These increases were however reversed with Garcinia kola pretreatment.  Amodiaquine 
administration increased the liver weight where as the heart, spleen and kidney were not significantly altered 
(Table 1).  Garcinia kola pretreatment also reduced the liver weight of the amodiaquine treated rat to 
pretreatment level. 
Figure1 is the result of the effect of administration of the drugs on serum cholesterol profile.  
Amodiaquine administration resulted in a significant increase in total cholesterol, LDL cholesterol, and 
triglyceride level.  HDL cholesterol was however not significantly altered.  With Garcinia kola pretreatment 
however, the values obtained for total cholesterol and LDL cholesterol were lowered, though the values 
obtained were still higher than the control values, where as the HDL cholesterol was not altered significantly.  
When Garcinia kola was administered alone, no change was observed in these parameters.  Similarly, artesunate 
administration significantly increased serum total cholesterol, LDL- cholesterol and triglyceride values, but 
lowered HDL- cholesterol.    When pretreated with Garcinia kola, artesunate administered rats did not show a 
significant alteration in these parameters from the values observed with sole administration of artesunate.  
Result for the hematological parameters is presented in Figure 2.  With artesunate administration, 
significant increases in fibrinogen and platelet count were observed, whereas the RBC and WBC count were not 
significantly affected.  Pretreatment with Garcinia kola however lowered the platelet count and the value of 
3.24±0.12x103/µL obtained was not different from the control value  (3.40±0.16 x103/µL).  This treatment 
however does not reduce the fibrinogen count from the values obtained with artesunate alone.  Neither 
administration of amodiaquine nor pretreatment with Garcinia kola significantly altered the RBC count.  
Amodiaquine administration however, significantly increased fibrinogen and WBC count.  The value of 7.24 
±0.04x103/µL observed for the WBC count was however still within the normal range for rat (5.5-11x10 3 /µL) 
The increase in fibrinogen and WBC count with amodiaquine was not reversed with Garcinia kola pretreatment, 
however the platelet count was reduced to the control value.  Sole administration of Garcinia kola does not 
significantly alter any of these parameters. 
Figure 3 illustrates the atherogenic (AI) and coronary risk index (CRI).  Both parameters were raised 
following administration of amodiaquine and artesunate.  Garcinia kola treatment had no significant influence 
on the AI and CRI.  Pretreatment with Garcinia kola did not alter the AI and CRI in the artesunate treated rats, 
as the value obtained was not different from the control values.  The values for these parameters   though still 
higher than the control values in the rats treated with Garcinia kola extract prior to amodiaquine administration, 
the values were however lowered compared with the values obtained when rats were administered with 
amodiaquine without prior treatment with Garcinia kola. 
 
 
Discussion 
 
Several Authors have reported on the hepatotoxicity effect of amodiaquine administration (Pero and 
Taylor, 2002; WHO, 1990), the present study also provide evidence in support of this and further report on the 
cardiotoxicity effect of administration of artesunate.  The increases in the relative liver weight of amodiaquine 
treated rat and relative heart weight of the artesunate treated rats observed in this study may be as a consequence 
of fat accumulation and may predispose the subject to arteriosclerosis.  John et al. (1999) reported that 
hypertrophy of the chronically loaded heart not accompanied by a new coronary capillary formation may lead to 
insufficient oxygen delivery to the cardiac muscle.  Hypertrophy can be caused by physiologic or pathologic 
condition and is caused by increased functional demand, which in the heart is usually chronic thymodynamic 
overload.  With continual enlargement, the heart will reach a stage when it will no longer be able to compensate 
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for the increased burden and cardiac failure will ensures (Cotran et al., 1999).  Data obtained for the lipid profile 
and haematological parameters further support this observation.  Hyperlipidemia has been noted as an important 
 
Table 1: Effect Of Treatment On Final Organ Weight 
 
Note: The results are the means ± SD for five (5) rats. Significant difference was carried out at p<0.05 
All values in the same column with same superscript are not significantly different from each other. 
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Group 
 
Treatment 
Final 
Body 
Weight 
(g) 
Heart Spleen Kidney Liver Stomach Heart Splee
n 
Kid
ney 
Liv
-er 
Stom
ach 
A Amodiaqui
ne 
(10mg/Kg) 
195.6±4.3
a 
0.58±0.0
2a 0.59±0.07a 1.27±0.03a 9.11±0.04a 2.64±0.38a 
0.29 0.30 0.6
5 
4.6
7 
1.35 
B Artesunate 
(5mg/Kg) 
207.7±2.1
a 
0.80±0.0
4b 0.85±0.07b 1.52±0.09b 6.64±0.31b 2.06±0.15a 
0.33 0.41 0.6
5 
3.2
1 
1.00 
C Normal 
Control 
(Normal 
Saline) 
216.8±8.5
a 
0.59±0.0
1a 0.59±0.04a 1.32±0.03a 6.48±0.17b 2.07±0.11a 
0.27 0.27 0.6
2 
3.0
0 
0.96 
D Garcinia 
kola 
(200mg/Kg) 
214.3±5.1
a 
0.57±0.0
2a 0.47±0.05c 1.13±0.06a 6.66±0.20b 2.16±0.17a 
0.27 0.34 0.5
3 
3.1
1 
1.01 
E Garcinia kola 
(200mg/Kg) + 
Amodiaquine 
(10mg/Kg) 
190.7±4.2
a 
0.58±0.0
2a 0.43±0.03c 1.22±0.06a 6.42±0.34b 2.27±0.15a 
0.31 0.33 0.5
7 
3.3
8 
1.19 
F Garcina 
kola 
(200mg/Kg
) 
+Artesunat
e (5mg/Kg) 
190.3±5.3
a 
0.61±0.0
1c 0.63±0.02a 1.08±0.06a 6.03±0.42b 2.09±0.08a 
0.35 0.42 0.5
8 
3.1
7 
1.10 
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Figure 1: Effect of Treatment on cholesterol profile The results are the means ± SD for five (5) rats. Significant 
difference was carried out at p<0.05. 
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        Figure.2: Effects of Amodiaquine and Artesunate on haematological parameters. The results are the means 
± SD for five (5) rats.Significant difference was carried out at p<0.05 
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Figure 3: Effect of Treatment on coronary risk and atterogenic index. The results are the means ± SD for five (5) 
rats. Significant difference was carried out at p<0.05 
 
 
metabolic risk factor for Ischaemic heart disease and ischemic cerebrovascular accident.  Literature has shown 
that there is a positive correlation between the risk of developing ischemic heart disease and raised plasma 
cholesterol and LDL cholesterol concentrations and a negative one with plasma HDL cholesterol.  Lowering 
plasma total cholesterol and LDL cholesterol concentrations reduces the risk of cardiovascular disease (Michael 
et al., 1998; Eun et al., 2002).   The increases in serum total cholesterol, LDL cholesterol and triglyceride level 
with a corresponding reduction in HDL cholesterol value with artesunate administration observed in this study 
indicate that treatment with artesunate predisposes to cardiovascular disease.  The cardiovascular disease risk 
with this drug is reported here to be higher than that with administration of amodiaquine in that with 
amodiaquine, HDL cholesterol was not reduced which was the case with artesunate administration.  It is 
important to note that pretreatment with Garcinia kola does not ameliorate this observed effect.  Hence, it could 
be emphasize here that though Garcinia kola have been widely reputed to be hepatoprotective, the extract may 
not be effective against cardiovascular disease risk. 
Serum fibrinogen is a component of the blood that plays a central role in clotting process (Cushma et 
al., 1996).  Recent results have shown that the level of fibrinogen and platelet count is independent 
cardiovascular factor (Mark et al., 1999; Passmore and Eastword, 1986).  Higher level of this parameter has 
been suggested may predispose the affected individual to develop clots in their arteries and platelet aggregation 
as increase plasma viscosity, thereby increasing the risk of a heart attack or stroke (Cushma et al., 1996).  
Artesunate administration is reported here to increase both fibrinogen and platelet count providing evidence for 
cardiovascular toxicity.   This effect is however mild with amodiaquine administration.  The study also suggests 
that this cardio- toxicity effect is not reversed with Garcinia kola pretreatment. Raised WBC count is seen in 
acute infections, metabolic disorders and drug use.  Since the observed WBC values reported here, both with 
amodiaquine, artesunate administration and with garcinia kola pretreatment are still within normal range, the 
drugs may not contribute to predisposition to infection. 
  The increased atherogenic and coronary risk index observed with administration of amodiaquine and 
artesunate could be attributable to increased LDL- cholesterol and total cholesterol values.  This also could 
suggest that both drugs when administered for prophylactic purposes may predispose to coronary disorders such 
as hypertension.  Occlusion of a coronary artery by lipid deposit has been reported to cause several local oxygen 
starvations and ultimately the degeneration of a localized portion of the heart muscle (Ernst, 1991). 
Garcina kola is also reported here not to be effective in reversing the artherogenic and coronary risk 
index in artesunate administered rat.  Data obtained however suggest that it may reduce the risk in amodiaquine 
treated rats.  We opined that the efficacy of the extract in amodiaquine treated rats may be due to the effect of 
interaction between metabolites of amodiaquine and kolaviron and that such interaction may not occurred with 
metabolite of artesunate. 
  
Conclusion 
 
Our study indicates that administration of amodiaquine and artesunate predisposes to cardiovascular 
disease.  This effect is however more pronounced with artesunate than with amodiaquine.  The study also 
reports that both amodiaquine and artesunate when administered for prophylactic purposes may predispose to 
artherogenic and coronary diseases and that Garcinia kola, though reputed to be heopatoprotective, is not 
effective against cardiovascular disease. 
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